Ankylosing Spondylitis (AS) is the leading chronic progressive inflammatory rheumatic disease that involves the sacroiliac joints (SIJs) and the spinal column but is often difficult to recognize in ...

Ivarmacitinib, a highly selective Janus kinase 1 (JAK1) inhibitor, tamed ankylosing spondylitis with sustained efficacy through 24 weeks in a phase 2/3 trial. A phase 2/3 trial in China evaluated the ...

In recent decades, major advancements have been made in our understanding of ankylosing spondylitis (AS). We now know how to diagnose it and how to manage it better. We can now diagnose AS earlier ...

Diagnosis of ankylosing spondylitis/axial spondyloarthritis (AS/axSpA) at an early stage is not a simple task and is often missed or markedly delayed, especially in a primary care setting, unless the ...

Repeat MRI scans found active inflammation in nearly half of patients with axial spondyloarthritis (axSpA) with ongoing symptoms, with inflammatory scans prompting treatment escalation or change more ...

A change in medication may cause new or worsening symptoms of ankylosing spondylitis, even if other symptoms improve. A doctor may need to prescribe a combination of medications to relieve a person’s ...